2025 Q3 -tulosraportti
66 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 414
Myynti
Määrä
22 290
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | AVA | NON | ||
| 100 | NON | NON | ||
| 264 | NON | NON | ||
| 1 000 | DDB | DDB | ||
| 2 424 | NON | NON |
Ylin
17,45VWAP
Alin
16VaihtoMäärä
6,4 381 138
VWAP
Ylin
17,45Alin
16VaihtoMäärä
6,4 381 138
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·15 t sitten · MuokattuLet me reiterate: There is no guarantee that this case will result in a sale or a major strategic partnership agreement! But the point is that when one looks at what Curasight is actually involved in, there is a significant discrepancy between the company's real position and the current share price. This asymmetry arises not only in one place, but across several key areas, which are largely not reflected in today's share price. Where does the case significantly deviate from today's share price: 1) Clinical position: Curasight is traded as “early biotech”, even though uPAR is already validated in hundreds of patients via uTRACE. Target risk is significantly reduced before therapy is complete. 2) Pipeline logic - The market sees one Phase I study. - The case is in practice diagnostics + therapy + basket strategy – i.e., platform, not single-asset. 3) IP and option value: Gen 2 uPAR and radionuclide extensions prolong exclusivity and increase option value. 4) Partner validation: Curium reduces CMC, supply chain, and regulatory risk, but the market prices the company as if these risks are still the same as before (Curium agreement = share price 9) 5) NDA asymmetry: Significant information is known under NDA, not public. Absence of news is therefore not equal to absence of progress. 6) Strategic optionality: The share price reflects the next data point – not strategic outcomes like partnership, basket, or sale. Boiled down to a bouillon cube Curasight deviates not only in one place, but across several key value drivers, which cannot – or must not – yet be reflected in the share price. This naturally does not guarantee a specific price/outcome, but it explains why today's share price can be a poor measure of the company's real value. It is precisely this asymmetry that I have been working with lately: Trying to understand where, how, and why the deviations arise – and with the help of AI, attempting to uncover and quantify the underlying values, based on empirical data, comparable cases (RayzeBio et al.) and observable behavior patterns in both Big Pharma and Top 3 in Curasight. ------------------------------------------------------------ 1. The asymmetry is structural – not temporary It is due to: • NDA • ownership structure • timing in relation to clinic and strategy → not “lack of interest” or “inefficiency”. B. The share price is a distribution question – not a value question The current share price determines who gets how much of the value, - but not IF it exists. The value is only realized by: • strategic agreement • transaction • or significant de-risking (e.g., basket). I hope this clarifies some of the questions raised in the forum. And no, I do not disclose my portfolios, for which one should I choose? They serve different purposes each. Would it bring credibility if I showed my newly created ASK portfolio that is maxed out with Curasight at share price 12,40, when I moved it over from DDB to avoid paying 27 % in tax (42-15), when Curasight is sold? All right then 😉
·11 t sittenYou will naturally pay tax on the return from your normal brokerage account when you sell them in 2026.. E.g., bought at 9 sold at 16 = 7,- per share, 27% is paid on the first 79,400 (2026) and 42% on your profit above that. But on your share savings account you only pay 17% of your subsequent profit. Assuming you currently have a profit of 100k, it can still be worthwhile to transfer them. Let's just assume, for example, that in half a year you have an additional 500,000 in profit. 17% of 500,000 instead of 42%.....easy math.... 😉
·19 t sittenThere's certainly someone who is happy to burn through 25 kr in brokerage.
·18 t sittenSome banks offer free trading if you have under 50000 kr, especially Swedish ones.
·20 t sitten3M revenue and it's not even 10 😅- ·21 t sittenAre we agreed that pump and dump can only happen with stocks where hedge funds and other big players have significant amounts of shares? Here the owners have 45% and private shareholders have something similar as far as I am aware
·21 t sittenYou've almost answered it yourself. Yes, there's less chance that Ulrich and Andreas will dump on you than a large hedge fund. That being said, it doesn't take much for it to fall. So a fall can easily happen, but the stock is so illiquid that it should be ignored. (just like it should have been ignored last year, around September - it was irrelevant whether it was at price 3-4 or 6-7 and it was irrelevant in Dec/Jan whether it was at 10 or 13.) The price can fluctuate right now, maybe it goes to 20 and then back to 15. That doesn't mean anything for the case itself and one should keep that in mind when intending to participate. One must know what the case is about and what one wants to do with it. It's the wrong case to buy into now at 17 if you don't understand that you're entering a very volatile world perhaps 
·21 t sittenJust a small side question. Is there no chance that Curasight will change stock exchange away from Spotlight, and wouldn't that be a big advantage? As I understand it, several platforms do not trade shares on Spotlight - wouldn't that be able to give an extra boost if it were on a more recognized exchange? Sorry if the question is stupid :- )·21 t sittenThat would probably enable larger players to buy in. So yes. But at the same time, it might also be a signal that a sale is not imminent. I think. Unfortunately, it would probably go against my gut feeling that tells me Andreas and Ulrich have the case exactly where they want it - and it will be launched before the end of the year. The gain for all involved will be significant. No buy recommendation, it's pure guesswork. Everyone should do what is good for themselves and make their own assessment.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
66 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·15 t sitten · MuokattuLet me reiterate: There is no guarantee that this case will result in a sale or a major strategic partnership agreement! But the point is that when one looks at what Curasight is actually involved in, there is a significant discrepancy between the company's real position and the current share price. This asymmetry arises not only in one place, but across several key areas, which are largely not reflected in today's share price. Where does the case significantly deviate from today's share price: 1) Clinical position: Curasight is traded as “early biotech”, even though uPAR is already validated in hundreds of patients via uTRACE. Target risk is significantly reduced before therapy is complete. 2) Pipeline logic - The market sees one Phase I study. - The case is in practice diagnostics + therapy + basket strategy – i.e., platform, not single-asset. 3) IP and option value: Gen 2 uPAR and radionuclide extensions prolong exclusivity and increase option value. 4) Partner validation: Curium reduces CMC, supply chain, and regulatory risk, but the market prices the company as if these risks are still the same as before (Curium agreement = share price 9) 5) NDA asymmetry: Significant information is known under NDA, not public. Absence of news is therefore not equal to absence of progress. 6) Strategic optionality: The share price reflects the next data point – not strategic outcomes like partnership, basket, or sale. Boiled down to a bouillon cube Curasight deviates not only in one place, but across several key value drivers, which cannot – or must not – yet be reflected in the share price. This naturally does not guarantee a specific price/outcome, but it explains why today's share price can be a poor measure of the company's real value. It is precisely this asymmetry that I have been working with lately: Trying to understand where, how, and why the deviations arise – and with the help of AI, attempting to uncover and quantify the underlying values, based on empirical data, comparable cases (RayzeBio et al.) and observable behavior patterns in both Big Pharma and Top 3 in Curasight. ------------------------------------------------------------ 1. The asymmetry is structural – not temporary It is due to: • NDA • ownership structure • timing in relation to clinic and strategy → not “lack of interest” or “inefficiency”. B. The share price is a distribution question – not a value question The current share price determines who gets how much of the value, - but not IF it exists. The value is only realized by: • strategic agreement • transaction • or significant de-risking (e.g., basket). I hope this clarifies some of the questions raised in the forum. And no, I do not disclose my portfolios, for which one should I choose? They serve different purposes each. Would it bring credibility if I showed my newly created ASK portfolio that is maxed out with Curasight at share price 12,40, when I moved it over from DDB to avoid paying 27 % in tax (42-15), when Curasight is sold? All right then 😉·11 t sittenYou will naturally pay tax on the return from your normal brokerage account when you sell them in 2026.. E.g., bought at 9 sold at 16 = 7,- per share, 27% is paid on the first 79,400 (2026) and 42% on your profit above that. But on your share savings account you only pay 17% of your subsequent profit. Assuming you currently have a profit of 100k, it can still be worthwhile to transfer them. Let's just assume, for example, that in half a year you have an additional 500,000 in profit. 17% of 500,000 instead of 42%.....easy math.... 😉
- ·19 t sittenThere's certainly someone who is happy to burn through 25 kr in brokerage.·18 t sittenSome banks offer free trading if you have under 50000 kr, especially Swedish ones.
- ·20 t sitten3M revenue and it's not even 10 😅
- ·21 t sittenAre we agreed that pump and dump can only happen with stocks where hedge funds and other big players have significant amounts of shares? Here the owners have 45% and private shareholders have something similar as far as I am aware·21 t sittenYou've almost answered it yourself. Yes, there's less chance that Ulrich and Andreas will dump on you than a large hedge fund. That being said, it doesn't take much for it to fall. So a fall can easily happen, but the stock is so illiquid that it should be ignored. (just like it should have been ignored last year, around September - it was irrelevant whether it was at price 3-4 or 6-7 and it was irrelevant in Dec/Jan whether it was at 10 or 13.) The price can fluctuate right now, maybe it goes to 20 and then back to 15. That doesn't mean anything for the case itself and one should keep that in mind when intending to participate. One must know what the case is about and what one wants to do with it. It's the wrong case to buy into now at 17 if you don't understand that you're entering a very volatile world perhaps
- ·21 t sittenJust a small side question. Is there no chance that Curasight will change stock exchange away from Spotlight, and wouldn't that be a big advantage? As I understand it, several platforms do not trade shares on Spotlight - wouldn't that be able to give an extra boost if it were on a more recognized exchange? Sorry if the question is stupid :- )·21 t sittenThat would probably enable larger players to buy in. So yes. But at the same time, it might also be a signal that a sale is not imminent. I think. Unfortunately, it would probably go against my gut feeling that tells me Andreas and Ulrich have the case exactly where they want it - and it will be launched before the end of the year. The gain for all involved will be significant. No buy recommendation, it's pure guesswork. Everyone should do what is good for themselves and make their own assessment.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 414
Myynti
Määrä
22 290
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | AVA | NON | ||
| 100 | NON | NON | ||
| 264 | NON | NON | ||
| 1 000 | DDB | DDB | ||
| 2 424 | NON | NON |
Ylin
17,45VWAP
Alin
16VaihtoMäärä
6,4 381 138
VWAP
Ylin
17,45Alin
16VaihtoMäärä
6,4 381 138
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
2025 Q3 -tulosraportti
66 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·15 t sitten · MuokattuLet me reiterate: There is no guarantee that this case will result in a sale or a major strategic partnership agreement! But the point is that when one looks at what Curasight is actually involved in, there is a significant discrepancy between the company's real position and the current share price. This asymmetry arises not only in one place, but across several key areas, which are largely not reflected in today's share price. Where does the case significantly deviate from today's share price: 1) Clinical position: Curasight is traded as “early biotech”, even though uPAR is already validated in hundreds of patients via uTRACE. Target risk is significantly reduced before therapy is complete. 2) Pipeline logic - The market sees one Phase I study. - The case is in practice diagnostics + therapy + basket strategy – i.e., platform, not single-asset. 3) IP and option value: Gen 2 uPAR and radionuclide extensions prolong exclusivity and increase option value. 4) Partner validation: Curium reduces CMC, supply chain, and regulatory risk, but the market prices the company as if these risks are still the same as before (Curium agreement = share price 9) 5) NDA asymmetry: Significant information is known under NDA, not public. Absence of news is therefore not equal to absence of progress. 6) Strategic optionality: The share price reflects the next data point – not strategic outcomes like partnership, basket, or sale. Boiled down to a bouillon cube Curasight deviates not only in one place, but across several key value drivers, which cannot – or must not – yet be reflected in the share price. This naturally does not guarantee a specific price/outcome, but it explains why today's share price can be a poor measure of the company's real value. It is precisely this asymmetry that I have been working with lately: Trying to understand where, how, and why the deviations arise – and with the help of AI, attempting to uncover and quantify the underlying values, based on empirical data, comparable cases (RayzeBio et al.) and observable behavior patterns in both Big Pharma and Top 3 in Curasight. ------------------------------------------------------------ 1. The asymmetry is structural – not temporary It is due to: • NDA • ownership structure • timing in relation to clinic and strategy → not “lack of interest” or “inefficiency”. B. The share price is a distribution question – not a value question The current share price determines who gets how much of the value, - but not IF it exists. The value is only realized by: • strategic agreement • transaction • or significant de-risking (e.g., basket). I hope this clarifies some of the questions raised in the forum. And no, I do not disclose my portfolios, for which one should I choose? They serve different purposes each. Would it bring credibility if I showed my newly created ASK portfolio that is maxed out with Curasight at share price 12,40, when I moved it over from DDB to avoid paying 27 % in tax (42-15), when Curasight is sold? All right then 😉·11 t sittenYou will naturally pay tax on the return from your normal brokerage account when you sell them in 2026.. E.g., bought at 9 sold at 16 = 7,- per share, 27% is paid on the first 79,400 (2026) and 42% on your profit above that. But on your share savings account you only pay 17% of your subsequent profit. Assuming you currently have a profit of 100k, it can still be worthwhile to transfer them. Let's just assume, for example, that in half a year you have an additional 500,000 in profit. 17% of 500,000 instead of 42%.....easy math.... 😉
- ·19 t sittenThere's certainly someone who is happy to burn through 25 kr in brokerage.·18 t sittenSome banks offer free trading if you have under 50000 kr, especially Swedish ones.
- ·20 t sitten3M revenue and it's not even 10 😅
- ·21 t sittenAre we agreed that pump and dump can only happen with stocks where hedge funds and other big players have significant amounts of shares? Here the owners have 45% and private shareholders have something similar as far as I am aware·21 t sittenYou've almost answered it yourself. Yes, there's less chance that Ulrich and Andreas will dump on you than a large hedge fund. That being said, it doesn't take much for it to fall. So a fall can easily happen, but the stock is so illiquid that it should be ignored. (just like it should have been ignored last year, around September - it was irrelevant whether it was at price 3-4 or 6-7 and it was irrelevant in Dec/Jan whether it was at 10 or 13.) The price can fluctuate right now, maybe it goes to 20 and then back to 15. That doesn't mean anything for the case itself and one should keep that in mind when intending to participate. One must know what the case is about and what one wants to do with it. It's the wrong case to buy into now at 17 if you don't understand that you're entering a very volatile world perhaps
- ·21 t sittenJust a small side question. Is there no chance that Curasight will change stock exchange away from Spotlight, and wouldn't that be a big advantage? As I understand it, several platforms do not trade shares on Spotlight - wouldn't that be able to give an extra boost if it were on a more recognized exchange? Sorry if the question is stupid :- )·21 t sittenThat would probably enable larger players to buy in. So yes. But at the same time, it might also be a signal that a sale is not imminent. I think. Unfortunately, it would probably go against my gut feeling that tells me Andreas and Ulrich have the case exactly where they want it - and it will be launched before the end of the year. The gain for all involved will be significant. No buy recommendation, it's pure guesswork. Everyone should do what is good for themselves and make their own assessment.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 414
Myynti
Määrä
22 290
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | AVA | NON | ||
| 100 | NON | NON | ||
| 264 | NON | NON | ||
| 1 000 | DDB | DDB | ||
| 2 424 | NON | NON |
Ylin
17,45VWAP
Alin
16VaihtoMäärä
6,4 381 138
VWAP
Ylin
17,45Alin
16VaihtoMäärä
6,4 381 138
Välittäjätilasto
Dataa ei löytynyt